MicroTech Medical(02235.HK): Continuous Glucose Monitoring System Secures Marketing Approval in South Korea

NewTimeSpace News: On 14 July 2026, MicroTech Medical(02235.HK) issued an announcement stating that the Company’s LinX continuous glucose monitoring system has recently been granted marketing approval in South Korea.

The Company stated that this approval will improve its market access layout across East Asia and lay a foundation for international business expansion and growth in overseas revenue. Nevertheless, product sales and earnings are subject to factors including market fluctuations, and investors are reminded to exercise prudence.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.